Back HCV Populations Injection Drug Users

Studies Reveal HIV and HCV Epidemics Among Injection Drug Users in the Middle East and North Africa

At least one-third of countries in the Middle East and North Africa that historically have had low rates of HIV infection now have emerging epidemics largely attributable to injection drug use, according to a systematic review published in the June 17 edition of the open access journal PLoS Medicine. Rates of hepatitis C virus (HCV) infection also appear to be high and rising.

alt

Read more:

CROI 2014: Monkey Studies Confirm Validity of Injectable PrEP

Two studies in monkeys of an injectable formulation of the third-generation integrase inhibitor drug GSK1265744 (or GSK744LA, where LA stands for "long-acting") have strengthened the evidence that it may work as pre-exposure prophylaxis (PrEP) in humans, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. A Phase 2 study in humans will be starting soon.

alt

Read more:

CROI 2014: Long-acting GSK744 Protects Monkeys against HIV-like Virus [VIDEO]

A long-acting injectable formulation of the next-generation integrase inhibitor GSK1265744 protected monkeys from infection via vaginal or anal exposure to a hybrid human-simian virus, according to 2 studies presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. These promising findings suggest this may be a future approach to pre-exposure prophylaxis (PrEP).

alt

Read more: